261 related articles for article (PubMed ID: 11007680)
21. [Treatment of renal anemia with iron in hemodialysis patients in General Hospital Bjelovar].
Lovcić V; Vujić J; Basić-Jukić N; Janković RI; Kurtović I; Dzapo M; Lovcić P
Acta Med Croatica; 2011 Oct; 65 Suppl 3():45-8. PubMed ID: 23120815
[TBL] [Abstract][Full Text] [Related]
22. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice.
Bhandari S; Naudeer S
J Eval Clin Pract; 2008 Dec; 14(6):996-1001. PubMed ID: 18785894
[TBL] [Abstract][Full Text] [Related]
23. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease.
Hood SA; O'Brien M; Higgins R
Nephrol Nurs J; 2000 Feb; 27(1):41-2. PubMed ID: 10852689
[TBL] [Abstract][Full Text] [Related]
24. [Optimizing iron therapy in hemodialysis: a prospective long term clinical study].
Siga E; Aiziczon D; Díaz G
Medicina (B Aires); 2011; 71(1):9-14. PubMed ID: 21296714
[TBL] [Abstract][Full Text] [Related]
25. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
26. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
Okonko DO; Grzeslo A; Witkowski T; Mandal AK; Slater RM; Roughton M; Foldes G; Thum T; Majda J; Banasiak W; Missouris CG; Poole-Wilson PA; Anker SD; Ponikowski P
J Am Coll Cardiol; 2008 Jan; 51(2):103-12. PubMed ID: 18191732
[TBL] [Abstract][Full Text] [Related]
27. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
28. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
29. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.
Park L; Uhthoff T; Tierney M; Nadler S
Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194
[TBL] [Abstract][Full Text] [Related]
30. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Multicenter Study Group, Israel.
Yagil Y
Isr J Med Sci; 1997 Jan; 33(1):36-44. PubMed ID: 9203516
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
32. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
33. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
34. A study of parenteral iron regimens in hemodialysis patients.
Besarab A; Kaiser JW; Frinak S
Am J Kidney Dis; 1999 Jul; 34(1):21-8. PubMed ID: 10401011
[TBL] [Abstract][Full Text] [Related]
35. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
36. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients.
Kaneko Y; Miyazaki S; Hirasawa Y; Gejyo F; Suzuki M
Kidney Int; 2003 Mar; 63(3):1086-93. PubMed ID: 12631092
[TBL] [Abstract][Full Text] [Related]
37. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
[TBL] [Abstract][Full Text] [Related]
38. Factor deficiency in the anemia of renal transplant patients with grade III-IV chronic kidney disease: baseline results of the ARES Study.
Gentil MA; Pérez-Valdivia MA; López-Mendoza M; Ortega F; Arias M; Gómez-Alamillo C; Campistol JM;
Transplant Proc; 2008 Nov; 40(9):2922-4. PubMed ID: 19010148
[TBL] [Abstract][Full Text] [Related]
39. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
40. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis.
Charytan C; Qunibi W; Bailie GR;
Nephron Clin Pract; 2005; 100(3):c55-62. PubMed ID: 15824508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]